ArticleThe open microbiology journal2011
Risk factors for severe respiratory syncytial virus lower respiratory tract infection.
Article in The open microbiology journal, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 127 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
127 citing papers in PubMed, 5 syntheses or guidelines pooled it, 253 citations in OpenAlex.
- Respiratory syncytial virus disease morbidity in Australian infants aged 0 to 6 months: a systematic review with narrative synthesis.BMC public health · 2023Pooled it
- Assessment of the Effects of Active Immunisation against Respiratory Syncytial Virus (RSV) using Decision-Analytic Models: A Systematic Review with a Focus on Vaccination Strategies, Modelling Methods and Input Data.PharmacoEconomics · 2021Pooled it
- The burden of respiratory syncytial virus (RSV) associated acute lower respiratory infections in children with Down syndrome: A systematic review and meta-analysis.Journal of global health · 2017Pooled it
- Respiratory syncytial virus hospitalization and mortality: Systematic review and meta-analysis.Pediatric pulmonology · 2017Pooled it
- Antibiotics for preventing lower respiratory tract infections in high-risk children aged 12 years and under.The Cochrane database of systematic reviews · 2015Pooled it
- Dynamics of Respiratory Syncytial Virus Illness and Serology During Pregnancy and Infancy in the United States and South Africa.Open forum infectious diseases · 2025Trial
- Altered regulatory cytokine profiles in cases of pediatric respiratory syncytial virus infection.Cytokine · 2018Trial
- RSV vaccine uptake among Medicare Advantage enrollees: August 2023 to December 2024.Human vaccines & immunotherapeutics · 2026Article
- Article
- Incidence of Respiratory Syncytial Virus Infection Among Patients Aged Less Than 2 Years: A Retrospective Study From an Italian Southern Region in Years 2018-2023.Influenza and other respiratory viruses · 2026Observational
- Article
- What Form of RSV Protection Do Women Prefer: Maternal Vaccination or Infant Immunisation? A Cross-Sectional Survey in Europe.Vaccines · 2026Article
- RSV-NTHi Co-Infection Skews Host Immunity by Suppressing Type I IFN Responses and Enhancing Pro-Inflammatory Responses.Pathogens (Basel, Switzerland) · 2026Article
- Epidemiology of moderate-to-severe respiratory syncytial virus infections in children in subtropical Okinawa, Japan: a 4-year retrospective study.Tropical medicine and health · 2025Article
- Age Matters: Key Contributors to Interferon Toxicity in Infants During Influenza Virus Infection.Viruses · 2025Review
- Pediatric respiratory syncytial virus rehospitalization rate - a retrospective observational study from Switzerland.BMC pediatrics · 2025Observational
- Risk Factors for Severe Disease Among Children Hospitalized With Respiratory Syncytial Virus.JAMA network open · 2025Observational
- Article
- Respiratory syncytial virus vaccines for toddlers and school-aged children: a pressing necessity for global health.Frontiers in pediatrics · 2025Article
- Observational
67 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
RSV infection is a leading cause of lower respiratory tract infection, especially in High-risk infants with a history of prematurity, bronchopulmonary dysplasia (BPD), congenital heart disease (CHD), neuromusculair impairment, immunodeficiency, and Down syndrome. Host related risk factors that have been identified to be associated with severe RSV related lower respiratory tract infection include young age below 6 months at the beginning of RSV season, multiple birth, male sex, low socioeconomic status and parental education, crowded living conditions, young siblings, maternal smoking and indoor smoke pollution, malnutrition/small for gestational age, family history of atopy or asthma, low cord serum RSV antibody titers, and living at altitude.Risk factors increasing the risk of acquisition of RSV have been identified to be birth before and/or during RSV season, day care attendance, presence of older siblings in school or day-care, and lack of breast feeding. Some of these risk factors are discussed controversially and some of them are found continuously throughout the literature.Given the high cost of RSV prophylaxis, especially for the large population of late preterm infants, algorithms and risk score systems have been published that could identify high-risk infants for treatment with palivizumab out of this gestational age group. Several models reported on an average sensitivity and specificity of 70 percent and, thus, are helpful to identify infants at high risk for severe RSV infection and need for prophylaxis with palivizumab.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.